Language Select
Varian Logo

heading
  • Security
Jan 24, 2017 | Ken Khouri, Director of Information Security
Healthcare organizations fight every day to save their patients’ lives. Protecting patient information is a different kind of fight. At Varian, we're working to develop software solutions that help make this data more secure so healthcare organizations can continue to focus on fighting cancer. Read more
  • Dr. William F. Regine, FACRO, FACR,  Isadore & Fannie Schneider Foxman Chair in the Department of Radiation Oncology at the University of Maryland; and Executive Director, Maryland Proton Treatment Center
Dec 13, 2016 | Dr. William F. Regine, FACRO, FACR
The Maryland Proton Treatment Center (MPTC) is off to a great start since opening in February of 2016. Learn from Dr. William Regine how MPTC built a foundation for success by developing relationships with local health systems and payers. Read more
  •  Dr. Mischa Hoogeman, R&D coordinator at HollandPTC and Head of medical physics at Erasmus Medical Center Cancer Institute
Nov 29, 2016 | Research Q&A, Dr. Hoogeman
HollandPTC will be the first proton center in the Netherlands once it opens in 2017. In this Q&A, Dr. Mischa Hoogeman describes the advances in proton therapy that will be offered at HollandPTC, including adaptive and image-guided techniques to improve efficacy. Read more
Nov 15, 2016 | Proton News
Comprised of radiation oncologists and physicists from around the world, the 20-member advisory board draws on their collective experience to provide clinical insights on proton therapy. Read more
Nov 01, 2016 | Research Q&A, Prof. Grau
The Danish Center for Particle Therapy will be a public, national research center, offering proton therapy free of charge to all appropriate Danish patients. In this Q&A, Cai Grau, DMSc, discusses how the face of radiotherapy care in Denmark is changing. Read more
  • Perentesis
Oct 19, 2016 | Research Q&A, Dr. Perentesis
In this Q&A, Dr. Perentesis shares his thoughts on some of the benefits of proton therapy research including reducing side effects and secondary cancers, as well as improving long-term outcomes. Read more